Senior Vice President, Research & Development
At Abcam, I have the privilege to lead all R&D activities, from strategy to product and technology development and governance.
In the past eight years, my team and I have supported the development of Abcam’s innovation, with the goal of directly helping to address the reproducibility crisis in the life sciences industry. Some of our key strategic initiatives include the implementation of recombinant production and the setup of multiple validation programs, including CRISPR gene-edited knockout cell lines, the gold standard for antibody validation. I’m very proud to say that some of these initiatives have received industry awards, reflecting our pioneering work on sustainability and performance at scale for antibody research tools.
In addition, I am actively involved in multiple global initiatives which goal is to promote good practice and to improve reproducibility: Antibody Society’s validation webinars, peer-reviewed manuscripts (mAbs, JBC), organizing and chairing Abcam’s ‘Reproducible Science Week’ virtual meeting, advising the open-science initiative YCharOS, etc.
Before joining Abcam, I held various positions at Merck-Millipore, latterly R&D Director, leading the Antibody and Assay Development teams. I also gained expertise in Immunology and Cell Signaling through postdoctoral fellowships at UCSF and the Trudeau Institute. I have a PhD in Immunology from UCL and an MSc in Biochemistry from the Instituto de Biotecnología UNAM.
Discover Abcam’s approach to support reproducible science, accelerate progress and reduce wasted resources.
Read more about Alejandra’s journey in this piece form Work180.